Viabahn VBX球囊扩张式内假体治疗髂动脉闭塞性疾病的长期随访
这项由研究者发起的多中心前瞻性单臂研究评估了Viabahn VBX球囊扩张式内假体治疗髂动脉闭塞性疾病的5年治疗持久性,共纳入59例受试者、94处病变。5年主要通畅率为89.5%(按病变)和84.4%(按受试者),免于靶病变血运重建率为89.1%。结论认为该内假体具有稳健且持久的疗效。
要点
- 5年主要通畅率按病变为89.5%,按受试者为84.4%。
- 5年免于靶病变血运重建的Kaplan-Meier估计值为89.1%。
- 5年随访时大多数受试者无症状(Rutherford 0级,18/28;64%)。
核心结论
- 5年长期随访数据强调Viabahn球囊扩张式内假体治疗主髂动脉闭塞性疾病的稳健性和持久性。
研究设计与样本
- 研究者发起的、来自参与前瞻性、多中心、非随机、单臂VBX FLEX临床研究(ClinicalTrials.gov标识符:NCT02080871)的3个主要招募中心的5年治疗持久性数据。
- 共纳入59例受试者、94处治疗病变,来自原VBX FLEX研究140例意向治疗受试者中的3个参与中心。
- 主要持久性终点为长期主要通畅率;次要长期结局包括免于靶病变血运重建、免于靶血管血运重建、静息踝肱指数、Rutherford分级、EuroQol 5维度量表及步行障碍状态。
主要发现
- 59例受试者参与,28例(47.5%)完成5年随访直至研究结束(因COVID-19预防措施导致的并发症,中位随访时间为6.6年)。
- 3年和5年全因死亡豁免的Kaplan-Meier估计值分别为94.5%和81.7%。
- 3年和5年主要通畅率的Kaplan-Meier估计值按病变分别为94.0%和89.5%,按受试者分别为91.7%和84.4%。
- 3年和5年主要辅助通畅率均为93.3%。
- 5年免于靶病变血运重建的Kaplan-Meier估计值为89.1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This physician-initiated study provides 5-year (i.e., long-term) treatment durability data from 3 top recruitment sites that participated in the prospective, multicenter, nonrandomized, single-arm VBX FLEX clinical study (ClinicalTrials.gov identifier: NCT02080871). It evaluates the long-term treatment durability of the GORE VIABAHN VBX Balloon Expandable Endoprosthesis (VBX Stent-Graft) in the treatment of subjects with de novo or restenotic aortoiliac lesions. MATERIALS AND METHODS: A total of 59 subjects with 94 treated lesions were enrolled at the 3 participating sites from the original 140 intent-to-treat subjects in the VBX FLEX study. The primary durability endpoint was long-term primary patency. Secondary long-term outcomes included freedom from target lesion revascularization (TLR), freedom from target vessel revascularization (TVR), as well as resting ankle-brachial index (ABI), Rutherford category, EuroQol 5 Dimensions, and Walking Impairment status. RESULTS: Fifty-nine subjects participated and twenty-eight (47.5%) were available through the end of the study at 5-year follow-up (the median follow-up time was 6.6 years due to complications resulting from COVID-19 precautions). At 3 and 5 years, the Kaplan-Meier estimates for freedom from all-cause mortality were 94.5% and 81.7%, respectively. The Kaplan-Meier estimates for primary patency at 3 and 5 years were 94.0% and 89.5% (by lesion) and 91.7% and 84.4% (by subject). Primary assisted patency at 3 and 5 years were 93.3% and 93.3%. Kaplan-Meier estimate for freedom from TLR at 5 years was 89.1%. The majority of subjects were asymptomatic (Rutherford category 0) at 3 years (29/59; 72%), and at 5-year follow-up (18/28; 64%). The 5-year mean resting ankle-brachial index was 0.95±0.18, an improvement of 0.15±0.26 from the baseline (p<0.001). Quality of life measures also showed sustained improvement through long-term follow-up. CONCLUSION: The 5-year long-term follow-up data underscore the robustness and durability of the Viabahn Balloon-Expandable Endoprosthesis for treating aortoiliac occlusive disease. CLINICAL IMPACT: Durable improvement after endovascular treatment of iliac occlusive disease is clinically important because many of these patients are claudicants with significant life expectancy. This study is the first to evaluate the long-term outcomes in patients with iliac occlusive disease treated with the Viabahn VBX balloon-expandable endopirostheses. The study reports excellent long-term patency outcomes with prolonged clinical benefit. These durable results are likely to be an important consideration for clinicians undertaking iliac artery revascularization procedures.
引用
- Holden A, Takele E, Hill A, et al. Long-Term Follow-up of Subjects With Iliac Occlusive Disease Treated With the Viabahn VBX Balloon-Expandable Endoprosthesis. J Endovasc Ther. 2023. PMID: 37073512. doi:10.1177/15266028231165723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。